Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Author
MaxCyte: Building the Future of Cell and Gene Therapy Innovation MarketBeat - Thu Jan 23, 6:00AM CST

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

CRSP : 43.42 (-1.83%)
MXCT : 4.66 (-2.10%)
VRTX : 439.62 (-0.03%)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire - Mon Jan 13, 2:05AM CST

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte Announces Retirement of Board Member Art Mandell GlobeNewswire - Mon Dec 23, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance Quiver Quantitative, Inc. - Mon Dec 9, 2024

MaxCyte completes operational review, streamlines workforce, increases 2024 revenue guidance, and focuses on cell therapy innovation.Quiver AI SummaryMaxCyte, Inc. has completed an internal operational...

MXCT : 4.66 (-2.10%)
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance GlobeNewswire - Mon Dec 9, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics GlobeNewswire - Wed Nov 13, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance GlobeNewswire - Wed Nov 6, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte to Participate in Two Upcoming Investor Conferences GlobeNewswire - Thu Oct 31, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
MaxCyte Appoints Cynthia Collins to its Board of Directors GlobeNewswire - Tue Oct 15, 2024

PSTX : 9.50 (-0.63%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (-80.00%)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)
CERT : 13.26 (+0.38%)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 GlobeNewswire - Fri Oct 11, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 383.920 (-5.20%)
MXCT : 4.66 (-2.10%)

Barchart Exclusives

Elon Musk Takes Aim at Oracle, SoftBank: Is ORCL Stock Still a Winner on Stargate News? Barchart - 1 hour ago
Oracle is poised to accelerate thanks to Stargate, cloud expansion, and its strategic edge. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot